Gossypol
Based on 11 publication(s) in Google Scholar
Gossypol binds to Bcl-xL protein and Bcl-2 protein with Kis of 0.5-0.6 μM and 0.2-0.3 mM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 303-45-7
- Formula: C30H30O8
- Molecular Weight:518.55
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Gossypol
More- Nat Commun. 2023 Jun 10;14(1):3445. [Abstract]
- Cell Rep. 2025 Apr 16;44(5):115572. [Abstract]
- Clin Transl Med. 2021 Jun;11(6):e467. [Abstract]
- Cancer Gene Ther. 2026 Jan 31. [Abstract]
- Toxicol Sci. 2025 Oct 24:kfaf149. [Abstract]
- Sci Rep. 2026 Feb 24;16(1):10361. [Abstract]
- Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
- Microb Pathog. 2024 Sep 21:106960. [Abstract]
- Transbound Emerg Dis. 2023 Nov 11:2023:9073566. [Abstract]
- Anticancer Res. 2026 May;46(5):2317-2327. [Abstract]
- Patent. US20220162561A1.
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Imaging/Staining
-
WB
Biological Activity
|
Bcl-xL 0.5-0.6 μM (Ki) |
Bcl-2 0.2-0.3 mM (Ki) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16-F10 | IC50 |
5.56 μg/mL
Compound: (R)-Gossypol
|
Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay
|
[PMID: 22739087] |
| Cancer cell lines | GI50 |
2.85 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| Cancer cell lines | GI50 |
2.97 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| Cancer cell lines | GI50 |
3.16 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| Cancer cell lines | GI50 |
3.19 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| Cancer cell lines | GI50 |
3.5 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| HEK293 | IC50 |
11.04 μM
Compound: AT-101
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27353532] |
| HeLa | IC50 |
0.08 μg/mL
Compound: 18
|
Cytotoxicity against human HeLa cells by SRB assay
Cytotoxicity against human HeLa cells by SRB assay
|
[PMID: 18553924] |
| HepG2 | IC50 |
10.16 μg/mL
Compound: (R)-Gossypol
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 22739087] |
| HL-60 | IC50 |
6.6 μM
Compound: AT-101
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27353532] |
| HT-29 | IC50 |
>5 μg/mL
Compound: 18
|
Cytotoxicity against human HT29 cells by SRB assay
Cytotoxicity against human HT29 cells by SRB assay
|
[PMID: 18553924] |
| K562 | IC50 |
4.55 μM
Compound: (R)-Gossypol
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25818766] |
| K562 | IC50 |
7.31 μM
Compound: Gossypol
|
Antiproliferative activity against human K562 cells by MTT assay
Antiproliferative activity against human K562 cells by MTT assay
|
[PMID: 26421995] |
| K562 | IC50 |
5.91 μM
Compound: Gossypol
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 26620718] |
| K562 | IC50 |
5.6 μM
Compound: Gossypol
|
Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
|
[PMID: 27810438] |
| K562 | IC50 |
8.28 μM
Compound: (-)-(R)-Gossypol
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 28233676] |
| KB | IC50 |
0.04 μg/mL
Compound: 18
|
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
|
[PMID: 18553924] |
| Leukemia cell | GI50 |
2.47 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| MCF7S | IC50 |
13.2 μM
Compound: Gossypol
|
Inhibitory concentration in MCF-7 cells
Inhibitory concentration in MCF-7 cells
|
[PMID: 13678404] |
| MDA-MB-231 | IC50 |
1.9 μM
Compound: 1
|
Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay
Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay
|
[PMID: 17552510] |
| MDA-MB-231 | IC50 |
3.7 μM
Compound: 2, R-(-)-gossypol
|
Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay
Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay
|
[PMID: 18237106] |
| MDA-MB-231 | IC50 |
9.21 μM
Compound: (R)-Gossypol
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 25818766] |
| MDA-MB-231 | IC50 |
4.8 μM
Compound: Gossypol
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 26421995] |
| MDA-MB-231 | IC50 |
9.42 μM
Compound: Gossypol
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 26620718] |
| MDA-MB-231 | IC50 |
9.23 μM
Compound: Gossypol
|
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
|
[PMID: 27810438] |
| MDA-MB-231 | IC50 |
8.54 μM
Compound: (-)-(R)-Gossypol
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 28233676] |
| MDCK | CC50 |
3.53 μM
Compound: Gossypol
|
Cytotoxicity against MDCK cells by MTT assay
Cytotoxicity against MDCK cells by MTT assay
|
[PMID: 22226654] |
| MDCK | IC50 |
2.14 μM
Compound: Gossypol, (-)/(+)-Gossypol
|
Antiviral activity against H5N1 subtype infected in MDCK cells
Antiviral activity against H5N1 subtype infected in MDCK cells
|
[PMID: 23538114] |
| Melanoma cell | GI50 |
3.22 μM
Compound: (+/-)-Gossypol
|
Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 27994761] |
| NCI-H1299 | EC50 |
6 μM
Compound: 1, Gossypol
|
Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay
Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay
|
[PMID: 19555126] |
| NCI-H460 | EC50 |
3 μM
Compound: 1, Gossypol
|
Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay
Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay
|
[PMID: 19555126] |
| PC-3 | IC50 |
2.5 μM
Compound: 2, R-(-)-gossypol
|
Growth inhibition of human PC3 cells after 4 days by WST-8 based assay
Growth inhibition of human PC3 cells after 4 days by WST-8 based assay
|
[PMID: 18237106] |
| PC-3 | IC50 |
6.71 μg/mL
Compound: (R)-Gossypol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 22739087] |
| PC-3 | IC50 |
6.26 μM
Compound: (R)-Gossypol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 25818766] |
| PC-3 | IC50 |
5.61 μM
Compound: Gossypol
|
Antiproliferative activity against human PC3 cells by MTT assay
Antiproliferative activity against human PC3 cells by MTT assay
|
[PMID: 26421995] |
| PC-3 | IC50 |
5.78 μM
Compound: Gossypol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 26620718] |
| PC-3 | IC50 |
7.54 μM
Compound: Gossypol
|
Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay
|
[PMID: 27810438] |
| PC-3 | IC50 |
8.58 μM
Compound: (-)-(R)-Gossypol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 28233676] |
| TZM | CC50 |
9.76 μM
Compound: Gossypol
|
Cytotoxicity in human TZM-bl cells by MTT assay
Cytotoxicity in human TZM-bl cells by MTT assay
|
[PMID: 22226654] |
| ZR-75-1 | IC50 |
8.4 μM
Compound: Gossypol
|
Inhibitory concentration in ZR-75-1 cells
Inhibitory concentration in ZR-75-1 cells
|
[PMID: 13678404] |
Gossypol, a natural product isolated from cottonseeds and roots that has been studied as an anticancer agent. The racemic form of Gossypol [(±)-Gossypol] is tested in several clinical trials and is well tolerated. The racemic form Gossypol ((±)-Gossypol) binds to Bcl-xL protein with a Ki of 0.5 to 0.6 μM. (±)-Gossypol also potently binds to Bcl-2 protein with a Ki value of 0.2-0.3 mM. The natural racemic Gossypol has two enantiomers, namely the (-)-Gossypol and (+)-Gossypol enantiomers. The racemic form and each of the enantiomers of Gossypol are tested against UM-SCC-6 and UM-SCC-14A in 6-day MTT assays. (-)-Gossypol exhibits greater growth inhibition relative to (±)-Gossypol than (+)-Gossypol in both cell lines tested (P<0.001). An intermediate growth inhibitory effect is observed with (±)-Gossypol but this effect is only observed at the higher dose of Gossypol (10 μM, P<0.0001)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 303-45-7
-
Appearance Solid
-
Molecular Weight 518.55
-
Formula C30H30O8
-
Color Light yellow to yellow
-
SMILES
O=CC1=C(O)C(O)=C(C(C)C)C2=CC(C)=C(C3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O)C(O)=C12
-
Synonyms
BL 193
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2023 Jun 10;14(1):3445. PMID: 37301862 -
Cell Rep
2025 Apr 16;44(5):115572. PMID: 40249703 -
Clin Transl Med
Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. [Abstract]2021 Jun;11(6):e467. PMID: 34185423 -
Cancer Gene Ther
C1orf35 contributes to high anabolic metabolism by simultaneously promoting aerobic glycolysis and oxidative phosphorylation in multiple myeloma cells. [Abstract]2026 Jan 31. PMID: 41620562 -
Toxicol Sci
Gossypol acetic acid affects locomotor activity by inducing mitophagy-related ferroptosis and apoptosis in zebrafish. [Abstract]2025 Oct 24:kfaf149. PMID: 41134649 -
Sci Rep
AT-101 inhibits the proliferation and invasion of tongue squamous carcinoma cells by targeting the miR-21-5p/FDX1 axis. [Abstract]2026 Feb 24;16(1):10361. PMID: 41735357 -
Food Chem Toxicol
Melatonin protects porcine oocytes from gossypol-induced meiosis defects via regulation of SIRT1-mediated mitophagy. [Abstract]2025 Jan:195:115122. PMID: 39571718
Gossypol purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
Representative images of cumulus expansion in Gossypol (0, 10, 20, 40 μM) -exposed oocytes after 44 h culture in vitro maturation.
Gossypol purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
(A) Illustrative images of ROS staining of Gossypol (0, 10, 20, 40 μM)-exposed oocytes. (B) Fluorescence intensity of ROS in control and gossypol treatment groups.
Gossypol purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
Expression of oxidative stress-related genes (CAT, GSH-Px, SOD1, and SOD2) in control and Gossypol (0, 10, 20, 40 μM) treatment groups in porcine oocytes.
Gossypol purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
Illustrative images of mitochondrial membrane potential (MMP) in Gossypol (0, 10, 20, 40 μM) -exposed oocytes.
Gossypol purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2025 Jan:195:115122. [Abstract]
Expression of PINK1/Parkin-mediated mitophagy related proteins (PINK1, Parkin and P62) of Gossypol (20 μM)-exposed oocytes treated with melatonin. Statistical analysis of the expressions of PINK1/Parkin-mediated mitophagy related proteins in control, gossypol treatment and gossypol-melatonin co-treatment groups.
-
Microb Pathog
2024 Sep 21:106960. PMID: 39313132 -
Transbound Emerg Dis
2023 Nov 11:2023:9073566. PMID: 40303819 -
Anticancer Res
Gossypol Inhibits GLI3-dependent SHH Signaling to Selectively Target SPOP-deficient Breast Cancer Cells. [Abstract]2026 May;46(5):2317-2327. PMID: 42049345 -
Solvent & Solubility
DMSO : 33.33 mg/mL (64.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Two representative UM-SCC cell lines, UM-SCC-6 and UM-SCC-14A, are continuously exposed to 0 (vehicle control), 5 or 10 μM (±)-Gossypol, (-)-Gossypol or (+)-Gossypol in a 6-day MTT cell survival assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9285 mL | 9.6423 mL | 19.2845 mL | 48.2114 mL |
| 5 mM | 0.3857 mL | 1.9285 mL | 3.8569 mL | 9.6423 mL | |
| 10 mM | 0.1928 mL | 0.9642 mL | 1.9285 mL | 4.8211 mL | |
| 15 mM | 0.1286 mL | 0.6428 mL | 1.2856 mL | 3.2141 mL | |
| 20 mM | 0.0964 mL | 0.4821 mL | 0.9642 mL | 2.4106 mL | |
| 25 mM | 0.0771 mL | 0.3857 mL | 0.7714 mL | 1.9285 mL | |
| 30 mM | 0.0643 mL | 0.3214 mL | 0.6428 mL | 1.6070 mL | |
| 40 mM | 0.0482 mL | 0.2411 mL | 0.4821 mL | 1.2053 mL | |
| 50 mM | 0.0386 mL | 0.1928 mL | 0.3857 mL | 0.9642 mL | |
| 60 mM | 0.0321 mL | 0.1607 mL | 0.3214 mL | 0.8035 mL |